Investigation for tyrosine kinase mutations using novel methods
Project/Area Number |
23659674
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Thoracic surgery
|
Research Institution | Nagoya City University |
Principal Investigator |
FUJII Yoshitaka 名古屋市立大学, 医学(系)研究科(研究院), 教授 (40156831)
|
Co-Investigator(Kenkyū-buntansha) |
SASAKI Hidefumi 名古屋市立大学, 大学院医学研究科, 准教授 (00336695)
YANO Motoki 名古屋市立大学, 大学院医学研究科, 准教授 (40315833)
矢野 智紀 名古屋市立大学, 医学(系)研究科(研究院), 准教授 (40315883)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2012: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2011: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
Keywords | EGFR / RET / NTRK1 / BRAF / CAST-PCR / Immunohistochemistry / V600E / NTRK / NRF2 / KIF5B/RET / 肺癌 / FISH / CISH |
Research Abstract |
Molecular targeted therapies such as crizotinib that target ALK fusion and erlotinib or gefitinib that target EGFR mutations have demonstrated superior single agent activity in selected patients as compared to standard chemotherapy regimes in lung cancer treatment. Recently, a series of new gene fusions have been described in patients with lung cancer associated with the kinase domain of the RET and NTRK1 gene using next generation sequencing. We have developed FISH method to detect RET fusions. In our cohort three RET fusion mutants were found, all were female, non-smoker and adenocarcinomas. Point mutation of the BRAF gene is a genetic event in a subset of lung cancer. In addition, BRAF V600E is a driver mutation that can be effectively targeted with selective BRAF and/or MEK inhibitors. To determine the BRAF mutation status in Japanese lung carcinoma, we investigated BRAF V600E mutations by real time-PCR (CAST-PCR) and immunohistochemical methods using mutation specific antibody.
|
Report
(4 results)
Research Products
(21 results)
-
[Journal Article] Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.2013
Author(s)
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Krykov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Janne P, Doebele RC.
-
Journal Title
Nature Medicine
Volume: 19
Issue: 11
Pages: 1469-1472
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer2012
Author(s)
Sasaki H, Shimizu S, Tani Y, Maekawa M, Okuda K, Yokota K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Fujii Y
-
Journal Title
Cancer Med
Volume: 1(1)
Issue: 1
Pages: 68-75
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-